Aethlon Medical, Inc. (AEMD) News
Filter AEMD News Items
AEMD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest AEMD News From Around the Web
Below are the latest news stories about AETHLON MEDICAL INC that investors may wish to consider to help them evaluate AEMD as an investment opportunity.
AEMD: Expect Focus on Oncology Studies; Cost Containment EffortsBy M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Expect no disruption from management change; increased emphasis on studying Hemopurifier® in oncology likely… Aethlon Medical (NASDAQ:AEMD) appointed CFO James Frakes as interim CEO. We expect no disruption as a result of the management change – Mr. Frakes has been with Aethlon since 2008 & knows the company well, in our view. |
Aethlon Medical, Inc. (NASDAQ:AEMD) Q2 2024 Earnings Call TranscriptAethlon Medical, Inc. (NASDAQ:AEMD) Q2 2024 Earnings Call Transcript November 14, 2023 Operator: Good day, and welcome to the Aethlon Medical Second Quarter Fiscal 2024 Earnings and Corporate Update Call. [Operator Instructions]. Please note this event is being recorded. I would now like to turn the conference over to Mr. Michael Miller with Rx Communications. […] |
Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate UpdateAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2023 and provided an update on recent developments. |
Aethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy Cipriani, M.B.A. as Chief Operating OfficerAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that James B. Frakes, M.B.A., Chief Financial Officer of the Company, was appointed as Interim Chief Executive Officer, replacing Charles J. Fisher, Jr. M.D. Mr. Frakes also was appointed as a member of the Board of Directors and will remain as Chief Financial Officer of the Company. Additionally, Guy Cipriani, formerly Chief |
Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening viral infections and for use in organ transplantation, today announced that it will issue financial results for its second quarter ended September 30, 2023, at 4:15 p.m. ET on Tuesday, November 14, 2023. |
AEMD: Authorization to Conduct Study in India Moves Oncology Initiatives AheadBy M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Clearance from India’s drug authority advances goal to study Hemopurifier® in patients with solid tumors Aethlon Medical (NASDAQ:AEMD) has received clearance from India’s central drug authority to conduct a phase 1 trial of the Hemopurifier® in patients being treated with checkpoint inhibitor therapy. Despite the many benefits of |
Aethlon Receives Clearance From Drug Controller General of India For Potential Phase 1 Trial of its Hemopurifier® in OncologyAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening viral infections and for use in organ transplantation, today announced that it has received clearance from the Drug Controller General of India (DCGI), the central drug authority in India, to conduct a phase 1 safety, feasibility and dose-finding trial of the company's Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti |
Aethlon Announces Reverse Stock SplitAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, effective at 5:00 p.m. ET on October 4, 2023. The Company's shares of common stock will begin trading on a reverse split-adjusted basis commencing upon market opening on October 5, 2023. |
Aethlon Medical to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that Steven LaRosa, M.D., Chief Medical Officer, and James Frakes, Chief Financial Officer, will present a company overview on Tuesday, September 12 at 4:30 PM EST, during the H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023, in New York City. |
AEMD: Focusing on Oncology, Infectious Disease & Organ Transplants InitiallyBy M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT R&D spending expected to go further by conducting current clinical efforts in Australia & India Aethlon Medical (NASDAQ:AEMD) is studying its lead product, the Hemopurifier®, in oncology, infectious disease and, reflecting a recent initiative, to determine the device’s ability to improve the outcomes of organ transplantation. AEMD |